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                                           INTRODUCTION 
Community-acquired  pneumonia (CAP) ,a relatively  easily treatable condition  
is still among the  top 10 killer diseases  competing with the likes of non –
communicable diseases which are not fully curable.   The scenario is 
particularly worse in the developing countries. Inspite of the antibiotic 
revolution , the mortality rates may be as large as 30-50%  in the 10% of the 
patients who may need intensive care . The morbidity associated with the 
disease is also enormous contributing much to the economical burden of the 
community. 
     
The secret of successfully managing the disease in a clinically and economically  
fruitful manner begins with identifying the patients who may need a higher level 
of care among a bigger group of patients who may be treated as out patients. 
This is particularly important because of the  extreme difference in the costs 
incurred in treating both these groups of patients. 
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The clinical prognostic indices like pneumonia severity index(PSI) and CRB-65  
have stood the test of time and are still being used in developing countries. But 
these are cumbersome and the observations may be examiner dependent. There  
arose a need for a reliable and quick laboratory based index which could help in 
triaging the patient. 
 
Various inflammatory markers like CRP , Procalcitonin have been analysed as 
potential candidates for triage because of the concept that  the  clinical  severity 
of pneumonia is proportional  to the inflammatory response. 
 
But there were other factors ,which also determine the severity of the disease.  
One important factor that could determine the severity is the extent of 
myocardial involvement .  Hence the cardiac biomarkers were used  in assessing 
the severity of pneumonia. The most useful of them are the natriuretic peptides 
and the most measurable of these peptides were BNP and NT- Pro BNP .  
 
The initial studies focused BNP as a marker of cardiac wall stress and hence a 
measure of the extent of myocardial involvement in the disease. But 
subsequently with the studies and experiments that showed that inflammatory 
cytokines and possibly hypoxia could also stimulate BNP release , there arose 
an interesting concept that BNP may be a surrogate marker of most of  the 
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factors that individually contribute to mortality and morbidity in pneumonia. 
The presence of renal failure in pneumonia could further elevate BNP levels. 
Though the cause for elevation of BNP in pneumonia is an interesting area of 
research , the severity of BNP rise is the concern in  pneumonia because it may 
be a measure of multiple poor prognostic factors like the severity of  
inflammation, hemodynamic imbalance and the presence of renal injury. Hence 
BNP may be a good marker for triaging the patients with pneumonia. The recent 
studies have stood by this idea, but studies in the Indian context are lacking 
 
 
Hence we aimed to analyse the prognostic implications of BNP levels in 
patients with community acquired pneumonia in a small group of patients by 
comparing it with a standard prognostic marker like CRB-65 . 
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        AIMS AND OBJECTIVES 
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                                       AIM OF THE STUDY 
 
 
1. To estimate serum BNP levels in patients diagnosed with community 
acquired pneumonia 
 
  
2. To analyze whether elevated BNP levels correlate with a higher mortality 
rate and a clinically severe disease as measured by the morbidity and 
outcomes. 
 
 
3. To compare serum BNP levels with CRB-65 score in predicting the 
clinical severity and mortality in pneumonia. 
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                         REVIEW OF LITERATURE 
Pneumonia is an infection of the pulmonary parenchyma
1
. Pneumonia is 
classified into  community-acquired pneumonia (CAP) in which the patient gets 
infected with the  pathogen outside the hospital and is usually diagnosed in less 
than 48 hours of admission  and  health care–associated pneumonia (HCAP) in 
which the person is supposed to have acquired the infection in the hospital and 
hence is diagnosed more than 48 hrs after admission.   
Pneumonia that occurs as a result of occurrence of infection because of 
proximity to or presence in a healthcare setup called hospital acquired 
pneumonia is further classified into two types. The first variety is  hospital-
acquired pneumonia (HAP) ,mostly acquired in a non ICU setting. The second, 
ventilator-associated pneumonia (VAP) is acquired when the person is put on 
ventilator support.  This is important because of  the  difference in etiological 
agents, treatment and hence the final outcome.
2
 
 Pneumonitis is inflammation induced by non-infectious cause, such as  
radiation or chemical injury
3
. The following literature will focus entirely  on  
community acquired pneumonia. 
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PATHOGENESIS: 
Pneumonia  results from microbial proliferation in the respiratory zones of the 
airway more specifically the alveoli 
4
. The organisms usually reach the lungs  
through the oropharynx or blood . As important as the microbe in  the  
pathogenesis of pneumonia is the inflammatory response of the host to the 
organism.  Inhalational pneumonia is most often due to microorganisms that 
 (1)  have high potential to survive in the body 
(2) have a smaller size 
(3) are immune to host defences
3 
.The severity of pneumonia depends on the the quantity and quality of  the 
bacteria in the inoculums  and the capability of the host defence to deal with 
them
2
. An intense inflammatory process ensues after propagation of organisms 
in the lower respiratory tract as determined by the aforementioned factors.  
The inflammatory process is mediated by proinflammatory cytokines such as 
TNF  and a series of interleukins (Interleukins-1,2, 6, and 8) 
7
and is balanced by 
anti-inflammatory mediators. Cytokines are responsible for the clinical and 
laboratory manifestations of bacterial pneumonia. 
 
15 
 
PATHOLOGY 
Pneumonia  can , pathologically and hence as a result clinically, be 
differentiated into typical and atypical pneumonias. Typical pneumonia is 
usually of bacterial origin and is characterised by neutrophilic infiltration of 
alveoli. Atypical pneumonias ,as caused by viruses , are usually associated with 
mononuclear and lymphocytic infiltration of the air spaces.
6
   
Anatomically and radiologically, pneumonia can be classified as 
bronchopneumonia and lobar pneumonia. In bronchopneumonia , infection 
usually spreads from bronchi to the alveoli. It may hence involve more than one 
lobe and the findings are patchy. Lobar pneumonia involves most of the 
airspaces of a single lobe. 
In the pre antibiotic era , pneumonia usually goes through a series of 4 stages:
6 
1. stage  of congestion – heavy congested lobes filled with protein rich 
exudates ,bacteria and very few pus cells 
2. stage of red hepatization  - a firm lung containing neutrophils , rbcs and 
fibrin 
3. stage of gray hepatisation- a dry lung filled still with purulent exudates 
4. stage of resolution- only cellular debris are found. 
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ETIOLOGY 
The etiological agent responsible for CAP cannot be identified in approximately 
50% of cases. the likely microbial causes of CAP differ according tothe severity 
of disease at clinical presentation
5
. S. pneumoniae, M. pneumoniae, 
Chlamydophila pneumoniae, and viruses are likely to cause mild CAP  whereas 
in patients with CAP severe enough to warrant hospitalization, S. pneumoniae is 
the most commonly identified etiologic agent followed by H. influenzae and M. 
pneumonia. Gram-negative enteric bacilli, S. aureus, Legionella spp., and 
respiratory viruses other than the influenza virus are uncommon, with an 
incidence of less than5%. Polymicrobial infections account for 10% to 20% of 
episodes 
Risk factors for CAP include alcohol intake , bronchial asthma, immune 
deficiency states, Smoking, underlying structural airway or parenchymal lung 
diseases,  and an age of 70 years versus 60–69 yrs.3 
Other comorbidities associated with increased rates of CAP and subsequent 
mortality include cardiac failure, renal failure , liver cell failure , neoplasms , 
diabetes, mental retardation , memory loss , cerebrovascular diseases  
immunodeficiency states and malnutrition . 
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CLINICAL FEATURES 
Pneumonia is characterized by the presence of fever, malaise , and respiratory 
symptoms such as cough (90%), sputum production (66%), breathlessness 
(66%), pleuritic pain (50%), and hemoptysis (15%)
2
. Hemoptysis is more often 
a feature of more severe necrotising forms of pneumonia
4
 . Elderly patients may 
have different clinical presentations and are more likely to present with 
confusion, weakness, failure to thrive, delirium, abdominal pain, or generalized 
deterioration of their clinical status. Symptoms like  headache, loose-stools, 
muscle pain, joint pains,  occur in 10–30% of patients as non-pulmonary 
manifestations
3,8
. Physical findings include tachypnea , tachycardia ,clinical 
evidence of consolidation like midline trachea ,  increased vocal resonance , 
tubular breathing , crackles , aegophony , and whispering pectriloquy 
corresponding to the areas of consolidation. 
CAP was historically classified as either typical or atypical. Typical pneumonia 
presented with acute onset of cough, purulent expectoration, breathlessness, 
pyrexia, prostration and was commonly associated with bacteria such as 
pneumococci, Hemophilus influenzae. On the other hand, atypical pneumonia 
was insidious in onset and was associated with dry cough, low grade fever, and 
mild dyspnea. It was caused by agents such as M pneumoniae and C 
pneumoniae. Choice of initial antibiotics was based on whether pneumonia was 
typical or atypical. 
18 
 
 
SEVERE COMMUNITY ASSOCIATED PNEUMONIA
3 
Of patients with CAP 8–10% require intensive care unit (ICU) management for 
respiratory and/or hemodynamic support. Pneumonia that requires care in an 
ICU is designated as severe CAP. End organ dysfunction is usually present and 
patients frequently require mechanical ventilation. The mortality rate of severe 
CAP ranges between 22% and 50%. 
Common Causes of Severe Community-Acquired Pneumonia in descending 
order of frequency are 
Streptococcus pneumoniae 
Enteric gram-negative bacilli 
Staphylococcus aureus 
Legionella spp. 
Mycoplasma pneumoniae 
Respiratory viruses 
Pseudomonas aeruginosa 
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RADIOLOGICAL FEATURES
2 
          The presence of air bronchograms and a lobar or segmental pattern is 
more characteristic of typical than atypical causes of pneumonia. In contrast, a 
mixed pattern (alveolar and interstitial disease) is more frequentlyobserved with 
atypical pneumonias 
LABORATORYEVALUATION;                                                                   
Evaluation of patients with pneumonia includes tests to identify the specific 
pathogen causing the infection as well as laboratory tests to determine the 
severity of illness and to monitor for dysfunction in extrapulmonary organs. 
Evaluation of patients with CAP who require hospitalization includes  complete 
hemogram ,  renal function tests , serum sodium levels, blood sugar levels,  liver 
function studies, and arterial blood gas analysis. 
 
MICROBIOLOGICAL  EVALUATION
3 
Identification of the infecting microorganism serves to verify the clinical 
diagnosis of infection and facilitates the use of specific therapy. Blood cultures 
are positive in only 10% of patients with CAP. Sputum gram stains are may 
guide the early antibiotic therapy in pneumonia giving a rough idea of the 
pathogens involved. But there is a high likelihood of contamination with oral 
and pharyngeal commensals.   
20 
 
 
The following is a guide to the battery of investigations to be done in a patient 
with CAP: 
 
OUTPATIENTS; 
None* 
 
 
HOSPITALISED PATIENTS: 
• Repeated blood cultures , atleast twice 
• Gram stain and culture of a valid sputum sample 
• Urinary antigen test for detection of Legionella pneumophila (in endemic 
areas or during outbreaks) 
• Stain for acid-fast bacilli and culture of sputum (if tuberculosis is suggested by 
clinical history or radiologic findings) 
• Fungal stain and culture of sputum, and fungal serologies (if infection by an 
endemic mycosis is suggested by the clinical history or radiologic findings) 
21 
 
• Sputum examination for Pneumocystis jirovecii (if suggested by clinical 
history or radiologic findings) 
• Serologies for M. pneumoniae, Chlamydia sp,  Coxiella burnetii, Legionella 
spp., and respiratory viruses (in endemic areas or during outbreaks) 
• Culture and microscopic evaluation of pleural fluid (if significant fluid is 
present) 
 
 
PATIENTS  UNDER INTENSIVE CARE
9 
• Sputum Gram stain and culture sensitivity, endotracheal aspirate, or 
bronchoscopically obtained specimens using a protected specimen brush or 
BAL if patient in a position to expectorate. 
• Other procedures as for other hospitalized patients 
INVASIVE PROCEDURES 
Because of  the higher rates of non- specificity of expectorated sputum,  an 
invasive procedure may be needed to obtain suitable material for microscopy 
and cultures. This may be important in the management of patients with life-
threatening CAP in whom diagnostic materials cannot otherwise be obtained  
22 
 
rapidly, patients with progressive pneumonia despite seemingly appropriate 
antimicrobial therapy, immunocompromised patients. 
 
Bronchoscopic Samples: 
 
 When compared with sputum cultures, routinely processed bronchoscopic 
specimens demonstrate improved sensitivity and equal specificity for the culture 
of pathogenic fungi and mycobacteria. However, such materials have 
unacceptably poor specificity for routine bacterial cultures owing to 
oropharyngeal contamination. In contrast, semiquantitative or quantitative 
cultures of materials obtained bronchoscopically with a protected sheath brush 
or through bronchoalveolar lavage (BAL) and by direct lung aspiration have 
been successfully used for aerobic and anaerobic bacterial cultures. A threshold 
of 103 CFU/mL has been recommended to distinguish colonization from 
infection in protected sheath brush cultures and 10
4 
CFU/ml in BAL fluid. 
 
 Transthoracic lung aspiration obtains specimens suitable for microbiologic and 
cytologic examination directly from lung parenchyma. It is a more successful 
method for diagnosing malignant pulmonary lesions than infectious diseases. 
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COMPLICATIONS: 
Common complications that can occur during the course of disease or later are 
Para-pneumonic effusions 
Empyema 
Lung abscess 
Acute respiratory distress syndrome 
Secondary  infections like meningitis, arthritis, endocarditis, pericarditis, and 
peritonitis. 
Nonpulmonary organ dysfunctions like renal failure, hepatic failure, 
disseminated intravascular coagulation, hemodynamic instability, and coma . 
DIAGNOSIS 
Pneumonia is a clinical diagnosis with symptoms of  dyspnea, cough with or 
without expectoration, fever or hypothermia, chest pain, and chills, with clinical 
examination suggestive of consolidation in most patients with presence of  
characteristic parenchymal infiltrate on chest radiograph
9
. 
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ASSESSMENT OF SEVERITY: 
Once the diagnosis of pneumonia has been made, the clinician must decide 
whether the patient can be managed in the outpatient setting or hospitalised.. 
Pneumonia is the fourth most frequent cause of hospitalizations
2
. It also remains 
a leading cause of mortality particularly in developing countries. In spite of the 
application of numerous and efficient antimicrobial drugs, the lethal outcome of 
community-acquired pneumonia (CAP) treated ambulatorily ranges from 0.6 to 
1.5%. In patients who require hospitalization, mortality rate ranges from 5 to 
13%. However, in case of development of complications and in artificially 
ventilated patients, the mortality rate rises up to 50%. Hence physicians started   
realising the need for a  accurate and quick predictor of poor outcomes and 
complications that might aid the physician on deciding   change in antibiotics 
and the level and intensity of care 
10
. Also  more than half of those patients with 
pneumonia may be treated on an out-patient basis ,  with oral drugs thus saving 
lot of manpower and resources. 
 
 A precise, objective model of pneumonia prognosis could help doctors estimate 
the risk for a particular  patient, as well as help them reach the decision 
regarding hospitalization
11
 The need for these prognostic scoring tools is 
motivated by extreme differences in costs of treating patients with CAP  in the 
25 
 
hospital , ICU  and as an outpatient
37
. Ninety percent of the estimated cost for 
care of pneumonia is related to inpatient expenses and the cost of hospitalizing 
an individual patient exceeds the cost of outpatient care by a factor of 15. 
 
OLDER PROGNOSTIC INDICES: 
The initial prognostic tools were based on history, clinical examination and 
basic investigations. In 1993, the American Thoracic Society identified risk 
factors that increased the risk of mortality or a downhill course for patients with 
CAP
14
.  They recommended inpatient therapy  if one or more of these factors 
were present. 
 
Factors in the history  
  Age greater than 65 years 
  Suspicion of aspiration 
  Cardiac failure 
  Bronchitis or emphysema 
  Diabetes mellitus 
   Alcohol abuse  
  Chronic renal failure 
   Liver cell dysfuction 
26 
 
  Previous splenectomy 
  Hospitalization during the prior 12 months 
  Altered mental status 
Physical findings  
  Temperature greater than 38.3°C 
  Tachypnea  greater than 30 breaths/p min 
   Systolic BP less than 90 mm Hg 
  Associated extra-pulmonary infections 
Laboratory abnormalities  
  Whitebloodcellcount<4or>30x10
9
 
  
 Hematocrit <30% 
 
  PaO2<60mmHg or PaCO2>50mmHg on room air 
  
  Blood urea nitrogen = 20 mg/dL or creatinine = 1.2 mg/dL 
 
IMAGING; 
  Multilobar or rapidly progressive radiographic infiltrates 
27 
 
.
 
But this method was highly unstructured and oversimplified . 
 
PNEUMONIA SEVERITY INDEX:  
Fine and colleagues developed a two step prognostic model which came to be 
known as pneumonia severity index (PSI)
13
. Here  they identified patients with 
no risk factors and assigned them to class 1 . Then they further stratified the 
patients to class 2 to class 5  depending upon the presence or absence of risk 
factors like higher age, history of coexisting conditions like cerebro vascular 
diseases, liver diseases, renal failure,congestive cardiac failure,neoplasms, signs 
on physical examination like  delirium, tachypnea , systolic BP , temperature, 
pulse rate and laboratory factors like  arterial pH,  BUN ,   serum Na
+
,  blood 
sugar, PCV ,  SpO2 and the presence of pleural effusion
3,14
. They assigned  
points for each of these variables as follows; 
Demographic factor    
  Age   
    Male Age in years 
    Female  Age in years –10 
    Hospital residents +10 
28 
 
Comorbidities
12,20 
  
  Malignancies  +30 
  Liver failure +20 
  Cardiac  failure +10 
  Cerebrovascular disease +10 
  Renal failure +10 
Clinical findings   
  Confusion  +20 
  Tachypnea > 30/min +20 
  Systolic blood pressure <90 mm Hg +20 
   Hypo or hyperthermia  <35°C or 40°C +15 
  Tachycardia > 125/min +10 
 Laboratory and radiographic findings    
  Acidosis  pH <7.35 +30 
  BUN > 30 mg/dL  +20 
   Serum Na 
+
 <130 mmol/L +20 
   Blood sugar >250 mg/dL  +10 
   PCV <30% +10 
29 
 
  Partial pressure of arterial oxygen <60 mm Hg +10 
  Pleural effusion +10 
 
A risk score is obtained by summing the patient's age in years (age -10 for 
females) and the points for each applicable patient characteristic. Patients with a 
score < 50 can be treated as outpatients , whereas those with scores > 90 need to 
be hospitalised. Proper management of patients with scores of 70–90 requires 
careful application of clinical judgment. 
 
Patients who have a PSI score of belonging to class I or II with a score of less 
than 70 have less than 1% chance of dying due to pneumonia in 30 days. They 
can be managed as outpatients with oral antibiotics. Patients with a PSI score of 
71 to 90  which assigns them to class III  have a 1 month  mortality rate of 
around 2.8% . they shall be admitted to hospitals and given a short course of 
oral or IV antibiotics with monitoring.  Hospital care is appropriate for patients 
with scores of 91 to 130 (class IV), who have a 30-day risk of death of 8.2% to 
9.3%, and for patients with a score of more than 130 (class V), who have a 30-
day risk of death of 27.0% to 31.1%. However, its calculation is burdensome 
and prone to individual errors.
16 
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The British Thoracic Society came up with their own prognostic algorithm 
which was simple and named it the CURB-65 score based on the variables on 
presentation that were taken into account.
15 
(1)  Confused state of mind(C) 
 
      (2) Urea levels in blood higher than 7 mmol/L (U) 
 
      (3) Respiratory rate  of 30/min or more(R) 
 
      (4)  hypotension with low systolic BP (<90 mm Hg) or  diastolic BP(<60 
mm Hg (B)  
 
     (5) Age 65 years or greater(65) 
 
Their algorithm assigns one  point for each of  these individual variables 
depending upon their  presence or absence. The cumulative score is calculated 
by making a sum of the points assigned  against the individual variables to a 
maximum score of 5. 
Scores  0 or 1 (group 1), 2 (group 2), and 3 to 5 (group 3) carry a 30 day 
mortality rate of 1.6%, 9.1%, and 23%, respectively. Outpatient treatment is 
recommended for  pts assigned to group 1 ,  group 2 patients require a short 
duration of inpatient care and monitoring, and intense monitoring  is 
31 
 
recommended for group 3 . Pts with scores of 4 or 5 shall be managed in an ICU 
setting. 
 
The IDSA and the ATS have published ICU admission criteria for patients with 
CAP. According to these criteria , ICU admission is warranted for patients who 
fulfill three minor criteria or one major criterion among the following criteria. 
Management of severe CAP per these guidelines has been associated with 
decreased mortality.
17 
 
MINOR CRITERIA 
Tachypnea > 30 breaths/min 
PaO2/FIO2 ratio < 250 
X –ray showing involvement of more than one lobe 
Delirium 
Renal failure (BUN level > 20 mg/dL) 
Reduced WBC count < 4000 cells/dL 
Reduced platelet count < 100,000 cells/dL) 
Fall in core body temperature to < 36
0
c 
Fall in BP requiring rapid volume replenishment 
MAJOR CRITERIA 
 Need for supportive ventilation 
Septic shock with need for pressor agents 
32 
 
 
 
INFLAMMATORY BIOMARKERS IN PNEUMONIA; 
  
The clinical and biochemical prognostic markers discussed above are 
cumbersome and most of them are useful in assessing mortality and morbidity 
in short term only.  Pneumonia is basically a disease in which there is a strong 
associated inflammatory response which also determines the clinical severity of 
the  disease and hence the final outcome. Hence the idea of using inflammatory 
biomarkers came on and they were put to test against the clinical and other 
biochemical  parameters.  In recent years biomarkers have come up in a big way 
in western countries  and they have been used for finding the etiological agent , 
assessing the severity and  prognosis  and making important decisions regarding 
the treatment.
18 
 
Leucocyte count was initially used as a the inflammatory marker to predict the 
prognosis. Further studies have used various relatively more advanced markers 
like C-reactive Protein, Procalcitonin , Arginin-vasopressin(C-terminal-proAVP 
-Copeptin), Natriuretic peptides , Adrenomedullin , Interleukin-6 & 10, 
Liposaccharide binding protein and serum cortisol levels for assessing the 
extent of inflammatory response, severity of the disease and hence the 
prognosis. 
33 
 
 
 
COMMON INFLAMMATORY BIOMARKERS: 
CRP is the  fore runner of the inflammatory biomarkers that were subsequently 
developed to assess the severity of pneumonia.  Any inflammation can lead to 
increase in CRP  as many  cytokines  promote its hepatic synthesis.. It is found 
in the serum very quickly , as early as 2 hrs , after the trigger. Measuring CRP 
level is a screen for infectious and inflammatory diseases.for this purpose it is 
better than WBC count and ESR. Rapid, marked increases in CRP occur with 
inflammation, infection, trauma and tissue necrosis, malignancies, and 
autoimmune disorders. But the problem with CRP is its poor specificity . The 
median serum concentration of CRP is 0.8 mg/l in normal human beings. CRP 
rises up to 50,000-fold in acute inflammatory states such as that found in 
pneumonia. 
 
Procalcitonin(PCT) is a peptide precursor of the hormone calcitonin, the latter 
being involved with calcium homeostasis. It is synthesized in the parafollicular 
cells of the thyroid. It is also produced like a cytokine by liver, and monocytes. 
PCT  is relatively specific for inflammation induced by bacterial infections as 
the viral infections and other tissue stressors do not stimulate the release of 
PCT. This is particularly helpful in deciding whether or not to use antibiotic 
therapy in a given case of pneumonia. 
34 
 
 
CARDIAC BIOMARKERS: 
Adrenomedullin (ADM) and Procalcitonin(PCT) belong to the same gene 
family, which may explain  their sensitivity and specificity to diagnose systemic 
bacterial infections.  ADM possesses immunomodulatory and bactericidal 
properties, and is one of the strongest endogenous vasodilators. 
 
Arginin-vasopressin (AVP) is usually measured via its prohormone fragment C-
terminal-proAVP (Copeptin) whose serum levels are significantly elevated in 
septic shock.
24 
 
NATRIURETIC PEPTIDES; 
Natreiuretic peptide family contains 4 members who share a common 17-
peptide ring structure. These are the atrial natriuretic peptide (ANP), brain 
natriuretic peptide (BNP) ,  C-type natriuretic peptide (CNP) and dendroaspis 
natriuretic peptide (DNP)
19
. Atrial natriuretic peptide(ANP) and Brain type 
natriuretic peptide(BNP) have been found to be useful in predicting the 
prognosis in patients with pneumonia.
21 
These are secreted by cardiac myocytes in response to volume or pressure 
overload of the ventricles and atria that impose excess stress on their walls .    
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ATRIAL NATRIURETIC PEPTIDE (ANP)
22 
ANP is also called  Cardionatrine, Cardiodilatine(CDD) or atriopeptin
23
.  It is 
released by  atrial myocytes in response to increased blood volume in atria. 
Other ANP secretagogues are sympathetic stimulation , hypernatremia, 
angiotensin-II and endothelin. Its fuctions are mediated by its action on its three 
receptors, NPR-A , NPR-B and NPR-C. ANP exerts its main actions in the 
kidneys by afferent  arteriolar dilatation, efferent arteriolar constriction, 
 mesangial relaxation , decreasing sodium reabsorption in the DCT   and cortical 
collecting duct  of the nephron ,  inhibiting renin secretion, reducing aldosterone 
secretion by the adrenal cortex. All these actions ultimately contributing to 
natriuresis and volume reduction. ANP has been studied in two different forms 
in assessing the severity of pneumonia.The N-terminal PRO ANP (NT Pro 
ANP) and the mid regional Pro ANP( MR Pro ANP). The MR Pro ANP is 
found to be more useful than the former in pneumonia.
24 
 
BRAIN TYPE NATRIURETIC PEPTIDE (BNP): 
 B-type natriuretic peptide,  secreted by the cardiac ventricles   whenever their 
walls are exposed to excessive stretch.  It is a polypeptide hormone containing  
thirty two aminoacids.The human BNP gene is located in the first chromosome 
and with the gene product being  proBNP
21
.  BNP got its name from porcine 
brain from which it was first  extracted  in 1988. Atrial myoctes have the  
highest ability to  produce BNP but ventricle wins the duel because of its 
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relatively higher muscle mass . Recent studies have shown that some BNP is 
secreted by fibroblasts also but their relative contribution is not known.   The 
ability to produce BNP  is induced in less than 60 mins in response to either 
pressure or volume overload of the heart.  Calcium ions play a role in the 
control of release of BNP.. BNP is secreted in combination NT-proBNP which 
is its cleavage remnant.. NT – pro BNP is biologically inactive. BNP acts on the 
same set of receptors like ANP , NPR-A and NPR-B and activates them. But it 
has ten times lower affinity than ANP on these receptors
26
. But  BNP stays in 
blood for longer period of time , infact around twice as long as that OF ANP  
making it ideal measurement and analysis.NT-Pro BNP has a similar advantage 
as compared to ANP. 
                  
FIGURE A. MOLECULAR STRUCTURE OF BNP 
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 BNP is cleared from the circulation by receptor-mediated endocytosis via the 
C-type natriuretic peptide receptor, as well as by enzymatic degradation via 
zinc-containing endopeptidases located on the vascular endothelial cells and in 
the renal tubules . As such BNP is mainly excreated through the kidneys leading 
to higher levels in cases of renal disease with or without failure. 
 
BIOLOGICAL FUNCTIONS OF BNP: 
The physiological effects of BNP are brought about by causing increased 
intracellular cyclic GMP production
27.
  Both the natriuretic peptides act mainly 
to counter  the  excess hemodynamic challenge imposed by the renin-
angiotensin system. The main action of BNP is on the kidneys and the 
vasculature as follows: 
Cardiovascular and Renal Actions of BNP 
 Sodium excretion 
 Free water clearence 
 Increasing  GFR & filtration fraction 
 Counteract renin release 
  Reduction in blood levels of  angiotensin II 
 Reducing   blood levels of aldosterone 
  Vasodilation in systemic vessels 
 Fall in systemic BP 
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 Venous hypotension 
 Reduced pulmonary capillary wedge pressure 
 
In addition the recent studies have focussed on the trophic effects of BNP on 
the heart. BNP is supposed to have protective effect against the detrimental 
fibrosis and remodelling that occurs in progressive heart failure. 
METHOD OF ESTIMATION OF BNP: 
BNP levels were initially assessed by  competitive radioimmunoassays .  this 
required  extraction and purification of the plasma sample.Second-generation 
assays  used  monoclonal antibodies and radioisotope labels. Third-generation 
assays used immunofluorescent methods . These provided results in as little as 
15 minutes
28
. 
 
FIGURE B. PHYSIOLOGICAL ACTIONS OF BNP 
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BIOCHEMICAL IMPORTANCE OF BNP: 
BNP was initially used as a biomarker in patients with acute dyspnea to 
differentiate cardiac causes from non-cardiac causes of dyspnea with values 
higher than 500 pg/ml almost diagnostic of a cardiac cause of dyspnea.
29
 
Subsequently it was found to have prognostic significance in such patients . 
This is due to the basic concept that BNP is a marker of cardiac stress and hence 
patients with higher BNP are supposed to have severe cardiac stress and hence 
poor prognosis. BNP accurately reflects current ventricular status, as its half-life 
is 20 minutes, as opposed to 1–2 hours for NT-ProBNP. So BNP was also used 
to monitor treatment response as well in congestive cardiac failure
30
. 
Closely related to these observations the further prognostic implications of BNP 
were described: 
 BNP was also useful in assessing other conditions like CAD with normal 
LV fuction.
31
 
 BNP was found to have important role in prognostication of millions of 
diabetics.
32
 
  BNP was used to assess the prognosis of heart surgery patients by 
determining the post operative complications and outcomes.
33
 
  Utility of BNP has also been explored in various emergency settings like 
preeclampsia, ICU and shock and ESRD.
34,35,36
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Subsequently other non-hemodynamic stimuli for the release of BNP were 
found like inflammatory cytokines and hypoxia and so the prognostic spectrum 
of BNP was expanded to other diseases that are mediated by acute inflammation 
and/or have associated hypoxia like COPD, sepsis and pneumonia. 
 
BNP IN PNEUMONIA : 
Ever since the advent of cardiac biomarkers for assessing the severity of 
pneumonia , there have been a few studies which have sought to analyse the 
prognostic importance of BNP in pneumonia by comparing it with clinical 
indices, biochemical parameters, inflammatory markers and other cardiac 
biomarkers. These studies have opened new avenues for further research and 
improved our understanding of the mechanism of BNP elevation in pneumonia 
and other conditions. 
BNP was found to be elevated in patients with pneumonia and it independently 
mirrored the severity of pneumonia as made out by other 
parameters. It was found to have more sensitivity and specificity when 
combined with other parameters in predicting the clinical course of illness. 
Elevated BNP was found to be an independent risk factor for mortality ,  
prolonged hospital stay , need for ICU monitoring ,delayed  clinical and 
radiological resolution . 
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Initially myocardial stress that a patient with pneumonia suffers was thought to 
be the main mechanism behind the elevated levels of BNP. But recent studies 
that have assessed the elevation of BNP in sepsis and the correlation of BNP 
with other inflammatory markers like CRP  have evoked the possibility of 
inflammatory cytokines like IL-6, IL-1, and TNF-α being important 
secretagogues for BNP in pneumonia. Further experimental studies have 
confirmed this finding and have suggested that this is the most important reason 
for elevation of BNP in pneumonia. 
Hypoxia was also expected to be an important factor in this setting but the 
subsequent studies failed to show any significant correlation. 
 
Currently as it stands reason for elevation of BNP in pneumonia may be one of 
the following: 
 Myocardial stress induced by pneumonia itself 
 Severe inflammation 
 Hypoxia 
 Presence of other organ dysfunction like renal failure or cardiac failure 
 
All these may complicate the course of pneumonia individually and is 
hypothesised that the cumulative effect of these factors is reflected in the levels 
of elevation of BNP depending upon their presence or absence. So BNP may be 
a one step test that says so much more than many factors combined.  
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The current guidelines promote the use of BNP in the risk stratification of 
congestive cardiac failure .  Clinico- biochemical parameters are still being used 
in case of pneumonia. BNP may appear a costly alternative but it is nevertheless 
simple, quick and effective and may play an important role in the future in 
assessing the prognosis of pneumonia. 
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 MATERIALS AND METHODS: 
 
 The study was conducted in the Rajiv Gandhi Government General Hospital, 
Chennai during the period between May 1, 2012 and October 31,2012. The 
entire study was  done on patients who were admitted under the care of Institute 
of Internal Medicine, Madras Medical College & Rajiv Gandhi Government 
General Hospital. 
The laboratory work and other investigations were done with the help of other 
departments which include: 
Institute of Biochemistry, MMC&RGGGH 
Institute of Pathology , MMC&RGGGH 
Barnard Institute of Radiology, MMC&RGGGH 
Institute of Microbiology, MMC&RGGGH 
Department of Cardiology, MMC & RGGGH 
 
Fourty two consecutive patients with community acquired pneumonia were 
selected  from our outpatient clinic and emergency ward as follows. 
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 Community acquired Pneumonia was diagnosed in a patient when he or she 
presents with 
1. One or more of the symptoms of pneumonia like fever, cough, dyspnea , 
hemoptysis or chest pain with  
2. Clinical examination showing features of consolidation and 
3. Radiological features of consolidation.  
and who does not meet the criteria for healthcare associated pneumonia. 
 
INCLUSION CRITERIA; 
1. All patients who fit into the description of community acquired 
pneumonia described above were included in the study. 
2. Age greater than 18 years. 
 
  EXCLUSION CRITERIA: 
  1.Patients who had history , clinical and Echo-cardiographic    evidence of   
heart disease 
  
 2.Patients with  clinical , biochemical and radiological evidence of acute kidney 
    injury or chronic kidney disease, with or without failure. 
 
 3. Patients with clinical and radiological evidence of COPD   
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4.Patients with previous history or radiological evidence of pulmonary     
tuberculosis. 
An elaborate history was obtained from all the patients and their relatives 
regarding the presenting complaints, their elaboration , past medical history 
including  diabetes mellites, systemic hypertension, ischemic heart  disease, 
seizures, CVA , tuberculosis , bronchial asthma and  COPD , retro viral disease 
, malignancies , prior surgeries and blood transfusion. Personal history, 
including alcohol intake, smoking , sexual habits and other adverse exposures 
,was elicited. 
 
All the patients underwent a thorough clinical examination from head to foot , 
including vital signs , SpO2, and detailed systemic examination , by two 
physicians to confirm the diagnosis and to pick up other relevant clinical 
findings.  
 
They underwent all the necessary investigations like renal function tests, liver 
functions tests, complete blood count, blood –culture and sensitivity, sputum or 
tracheal aspirate – gram stain, culture and sensitivity, ECG, Chest X ray, USG 
abdomen , ECHO - cardiogram when there was a doubtful cardiac disease , CT- 
chest whenever the diagnosis is in doubt. The BNP levels on admission was 
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measured by using immune-fluorescence method. The choice of antibiotic usage 
and other treatments were left to the treating physician .  
 
The patients were re-examined after 4 weeks in all the possible cases and the 
records were analysed in the other cases for resolution or persistence of 
symptoms , signs and radiological features. The duration of hospital stay was 
obtained from the records. In those who died during the follow up period , the 
records were analysed comprehensively and information gathered. 
 
Statistical Analysis : 
 All the analysis were done using the statistical package - SPSS Software. 
 
 
  
Consent 
 Written and informed consent were obtained from  all the participants in 
feasible cases  or their attenders . 
 
 
 
Ethical Committee Approval 
The study was approved by Institutional Ethics Committee of Madras Medical   
college . 
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                   OBSERVATION AND RESULTS: 
 
The study results were tabulated and a stepwise analysis performed beginning 
with the analysis of BNP levels in survivors and non- survivors. Since the BNP 
levels in the non-survivors were eccentric and confounding the analysis of BNP 
with other variables , the further comparisions in BNP used values from the 
survivors only. 
 
The mean values in all the analysis were compared using the two- tailed 
unpaired t test and the level of significance assumed was 0.05. 
 
The following variables were included in the analysis; 
Age , sex, presence of co-morbidities, h/o prior antibiotic administration, 
alcoholism , smoking ,CRB-65 score ,  Total leucocyte count , BNP levels , 
cultured organism, duration of hospital stay, clinical and radiological resolution 
development of complications like pleural effusion , empyema , MODS, ARDS 
and mortality. 
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                    RESULTS 
1. The mean BNP levels in male survivors was compared with that of 
female survivors.                
 
FIGURE.1.Number of males and females in the study and  their    
relative  survival  percentage 
 
There were 25 males and 17 females enrolled in the study.There were 19 male 
patients who survived the episode of pneumonia among the 25 males which 
amounts to 76%. 15 0f the 17 females(88%) survived . 
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The mean BNP level in male survivors was 160.32pg/ml with a standard 
deviation of  72.08 as against a mean BNP of 134.3pg/ml with a standard 
deviation of 44.77 in female survivors . The two tailed P value between the 
means was 0.23 which was insignificant with  95% confidence interval. Thus 
there was no significant sex influence on BNP. 
SEX MALE  FEMALE 
SAMPLE SIZE 19 15 
MEAN BNP(PG/ML) 160.3 134.3 
STANDARD 
DEVIATION 
72.08 44.77 
         TABLE 1. Comparision of mean BNP in male survivors with BNP                  
                    levels in female survivors  
                            
  
 FIGURE 2.Mean BNP in males vs females 
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2. The mean BNP in age groups greater than 50 and less than or equal to 50 
were compared.  There were 17 patients in the age group 50 or less and 
25 patients above 50 years. 
 
FIGURE.3.Comparision of relative mortality in age groups >50 and 
less   than or equal to 50 
 
AGE >50 < OR =50 
NUMBER 20 14 
MEAN BNP 138.3 163.2 
     TABLE 2.Mean BNP in age groups >50 and <or =50 in those 
                       who survived 
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There were 5 deaths among those in age group more than 50 and 3 deaths in the 
other group, constituting 20% and 17% respectively. 
The mean BNP levels in the survivors over the age of 50 was 138.3 pg/ml as 
against a mean of 163.2 pg/ml in those less than or equal to 50 years. Their 
standard deviations are 41.2 and 83.3 respectively. The two tailed P value for 
this variables was 0.27 which showed that age did not have any significant 
influence on the BNP levels. 
 FIGURE 4.  Mean BNP in age groups >50 and <or =50 in those who 
                           survived 
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3.The BNP levels in those who had co-morbidities that are not known to 
increase BNP were compared with the levels in those without any 
comorbidities. The conditions that were included are underlying malignancies 
diabetes mellites, systemic hypertension , previous CVA. There were 23 
patients who had one morbidity or the other with diabetes being the commonest  
occurring in 15 patients. 8 patients had more than one comorbidity. The 
malignancies that were encountered were lung and gi malignancies.   
 
FIGURE 5.Distribution of comorbidities in the study population 
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There were 6/25 deaths in those with  any one of the comorbidities compared to 
2/19 deaths in those with no comorbidities.  
 
 
FIGURE.6 Correlation between no.of comorbidities and mortality 
TABLE.3. Correlation of comorbidities with mean BNP levels. 
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TOTAL PATIENTS 25 19 
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S.D 54.8 70.4 
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The mean BNP in patients with comorbidities was 148.7pg/ml against an almost 
similar value of 149.2pg/ml in patients with no comorbidities thus confirming 
that these diseases do not have any notable influence on the BNP levels. The P 
value was 0.9 and it was not needed in this case to decide the significance 
factor. 
 
 
FIGURE7;  Mean BNP in survivors with and without comorbidities  
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4.The mean BNP in surviving smokers and non-smokers were compared.  
There were 13 smokers in the study of whom 9 survived with a mortality rate 
of 31%.  The mortality rate among 29 non smokers was 13% 
 
SMOKERS YES NO 
NUMBER 9 25 
MEAN 133.3 154.4 
SD 74.2 57.8 
TABLE  4.Mean  BNP in smokers and non smokers among survivors 
 
 
 
FIGURE 8. Mortality comparisions in smokers vs non-smokers 
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The mean BNP in surviving  patients with history of smoking was 133.3 pg/ml 
with a standard deviation of 74.2. The mean BNP in non smoking survivors was 
154.4pg/ml with a standard deviation of 57.82pg/ml.  the P value on comparing 
the means was 0.39 which showed that there was no meaningful increase or 
decrease in BNP in patients who smoke. But the lower mean BNP was a 
surprising value. 
 
 
FIGURE 9.Mean BNP in smokers vs non- smokers in survivors. 
5. The mean BNP in alcoholics who survived were compared to that of the non 
alcoholics who were alive. There were 15 alcoholics in the study with 14 of 
them being males. 14 of alcoholics survived the illness which was better than 
the survival rate of  the 20 of the 27 non alcoholics who survived.  
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ALCOHOLIC YES NO 
TOTAL NUMBER 15 27 
SURVIVORS 14 2O 
MEAN BNP 161.2 140.8 
TABLE 5.Mean BNP in alcoholics and non-alcoholic survivors 
The mean BNP in alcoholics who survived was 161.2pg/ml  against a value of 
140.8 pg/ml seen in non-alcoholics with a P value of 0.34 which showed that 
there was no significant influence of alcohol on the BNP level 
 
FIGURE 10.Mean BNP levels in alcoholics and non-alcoholic survivors 
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6. The mean BNP levels in survivors who were previously treated with 
antibiotics when they presented to the hospital were comparitively analysed 
with that of those who did not receive any antibiotics. 24 patients who presented 
to the emergency room had received some form of antibiotic therapy prior to 
coming to our institute. Infact all the 8 patients who died during the follow up 
period had received some  prior anti-biotics. This observation can be explained 
by the level of care for which the patients in poor shape are being referred after 
initial antibiotic therapy.  
PRIOR-ANTIBIOTICS YES N0 
NUMBER 16 18 
MEAN 162.9 136.4 
S.D 55.06 66.81 
TABLE 6.Mean BNP levels in survivors who received prior antibiotics vs    
those who were untreated. 
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FIGURE 11.Mean BNP levels in survivors who received prior 
 antibiotics vs those who were untreated. 
 
7.  The survival rate of patients who had an SpO2 of more than 90 0n 
presentation was analysed and the mean BNP level in survivors with an SpO2 
of more than 90 was compared with that of persons with SpO2 less than  90  to 
find out if there was any relation between hypoxia and BNP release.  
26 patients had an Sp02 of more than 90 and all of them survived. But there was 
50% mortality in those persons who had an SpO2 of less than or equal to 90 at 
presentation. 
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 FIGURE 12.Correlation between SpO2 and mortality 
The mean BNP level in survivors with SpO2 was 174.7 pg/ml with a standard 
deviation of 48.6 against a mean value of 140.9 pg/ml with a standard deviation 
of 64.4 in those with SpO2 of less than or equal to 90. 
 
SpO2 >90 < OR = 90 
NUMBER 26 8 
MEAN BNP 140.9 174.7 
TABLE 7.Mean BNP levels in survivors with SpO2 greater than 90 vs less   
than or equal to 90 
 
The P value was 0.18 which showed that the difference was not that significant 
So the possibility of hypoxia being a stimulator of BNP received a jolt. 
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FIGURE 13., Mean BNP levels in survivors with SpO2 greater than 90 vs 
less   than or equal to 90  
 
8.The relative commonness of the nature of organism isolated was studied and 
any difference in the mean BNP levels of the two common group of organisms 
was analysed. 
Of the 42 patients in the study, 17 patients harboured gram positive cocci with 
strep. Pneumoniae and Staph.aureus being the commonest. 10 patients were 
infected with gram negative bacilli like Pseudomonas or Klebsiella and 1 
patient was found to have both these groups of bacteria.  In 14 patients no 
organisms were isolated by routine gram stain and culture methods. 
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FIGURE 14.Relative frequencies of the causative group of organisms in 
pneumonia 
The mean BNP in patients whose culture showed gram positive cocci was 
127.6pg/ml .The mean BNP in patients with gram negative bacilli was 
173.9pg/ml. the P value of the difference between the means was 0.102 . 
Though the difference was insignificant , there seems to be a greater tendency 
for the gram negative bacilli. 
ORGANISM GPC GNB 
NUMBER 14 10 
MEAN 127.6 173.9 
TABLE. 8.Mean BNP in survivors infected with gram positive cocci vs 
gram negative bacilli. 
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FIGURE 15. Mean BNP in survivors infected with gram positive cocci vs 
gram negative bacilli 
 
9.The correlation between BNP levels and leucocyte count was studied to find 
out if there was any relation between the inflammatory response and the levels 
of BNP.The mean BNP in survivors with leucocyte count of more than 15,000 
was compared with that of those patients with a leucocyte count of more than 
15,000.The leucocyte count was highly variable in the study varying from as 
low as 2100 cell/mm
3 
to as high as 28,200 cell/mm
3 
and either extremes of 
values can be explained by pneumonia itself 
 
 
173.9 
127.6 
10 14 
0 
20 
40 
60 
80 
100 
120 
140 
160 
180 
200 
GNB GPC 
MEAN BNP 
SAMPLE SIZE 
66 
 
LEUCOCYTE 
COUNT 
>15,000 /mm
3 
<15,000/mm
3 
SURVIVORS 9 25 
MEAN BNP 200.4 130.2 
TABLE 9. Mean BNP in survivors  with or without  leucocytosis (>15,000) 
 
 
The mean BNP in the 25 patients who survived with a leucocyte count of 
greater than 15,000 was 130.24pg/ml against a mean BNP of 200.4pg/ml in the 
9 survivors with leucocyte count less than 15,000. The probability of this 
difference occurring by chance was 0.002 by two tailed paired t test. This shows 
that the release of BNP correlated well with the rise in leucocyte count. This 
emphasises the close relationship between BNP levels and inflammation.  
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FIGURE 16.Mean BNP in survivors with or without  leucocytosis (>15,000)  
 
10.Having studied the correlation of BNP levels with the inflammatory response 
, the correlation between the BNP levels and clinical severity as assessed by 
CRB-65 score was analysed. The mean BNP in survivors with a CRB-65 score 
of 0 and 1 was compared with that of those with a score of 2 and 3. 
CRB-65 SCORE 0 OR 1 2 or 3 
NUMBER 19 15 
MEAN BNP(pg/ml) 119.3 186.2 
TABLE10.Mean BNP  levels in persons with CRB scores 0 or 1 vs 2 or 3 
among the survivors. 
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 The mean BNP levels in survivors with CRB-65 score of 0 or 1 was 119.3 
against a mean of 186.2pg/ml in survivors with a score of 2 or 3. 
 
 
FIGURE17.Comparision of mean BNP  levels in persons with CRB scores 0 
or 1 vs 2 or 3 among the survivors 
  
The P value for this set of means was 0.009 which showed that there was 
significantly higher levels of BNP in patients with a higher CRB-65 score thus 
ascertaining the fact that BNP levels varied directly with the clinical severity of 
pneumonia.  
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11. Having studied the variation of BNP levels with varied parameters in 
pneumonia, we analysed the BNP levels with the outcomes at after 4 weeks of 
follow up. First the correlation of BNP levels with clinical resolution of all the 
symptoms of pneumonia and its sequlae was studied in the survivors.  
CLINICAL 
RESOLUTION 
YES NO 
NO.OF.PATIENTS 27 7 
MEAN BNP(pg/ml) 133.48 208.1 
TABLE 11.Comparision of BNP in patients with and without clinical 
resolution among survivors 
 
27 of the 34 survivors had clinical resolution of all the symptoms after 4 
weeks.The mean of their initial BNP was 133.48pg/ml. 7 patients had some 
persisting symptoms in the form of either persisting cough , malaise or fatigue 
that prevented them from pursuing their occupation. The mean BNP level in 
them was  208.1 pg/ml. The P value for the difference between the means was 
0.003 . Thus there was significant correlation between BNP levels at 
presentation and the rate and extent of clinical resolution.   
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FIGURE 18. Comparision of BNP in patients with and without clinical 
resolution in survivors 
12. The mean BNP levels were compared in patients who had complete 
radiological resolution and the patients who had persistent opacities at the end 
of 4 weeks to determine whether the BNP levels on presentation correlated with 
the rate of radiological resolution. 
RADIOLOGICAL 
RESOLUTION 
COMPLETE INCOMPLETE 
NO.OF SURVIVORS 13 21 
MEAN BNP(pg/ml) 113.7 170.52 
TABLE 12. Comparision of BNP in patients with and without  radiological 
resolution in survivors 
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Among the 34 survivors, 13 patients(38%) had complete radiological resolution. 
The mean BNP in this group of patients was  113.7pg/ml. The mean BNP in the 
remaining 21 survivors without complete radiological resolution was 
170.52pg/ml.  The possibility that this difference has occurred by chance was 
found to be 0.0075 as determined by the two tailed value. This shows that there 
was a good correlation between BNP levels and the rate of radiological 
resolution. 
 
FIGURE 19. Comparision of BNP in patients with and without  
radiological resolution in survivors. 
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13. The mean BNP levels in the survivors who had a hospital stay of more than 
10 days was compared with that of the survivors who had a stay of less than or 
equal to 10 days. This was done to analyse whether BNP levels on admission 
can predict the length of hospital stay.  
 
    
FIGURE 20.The distribution of BNP values in consecutive patients as a 
function of the duration of hospital stay. 
 
 
13 of the 34 survivors had a stay of more than 10 days in the hospital with the 
maximum being 20 days.The mean admission BNP in this group was 
196.2pg/ml against a mean BNP of 119.2pg/ml in the 21 patients who stayed for 
less than or equal to 10 days. The P value for the difference between the means 
0 
50 
100 
150 
200 
250 
300 
350 
10 5 7 14 15 4 5 4 17 4 9 20 7 8 12 8 8 
DURATION OF HOSPITAL STAY IN DAYS 
BNP ON ADMISSION 
BNP ON ADMISSION 
73 
 
was 0.0001 which shows that a higher BNP level on admission predits a longer 
stay in hospital and a lengthier course of antibiotics.  
DURATION OF STAY 
IN HOSPITAL 
> 10 DAYS < 0R=10 DAYS 
NO. OF PATIENTS 13 21 
MEAN BNP(pg/ml) 196.6 119.2 
TABLE 13. Mean BNP in patients with a hospital stay of >10 days and < or 
= 10 days among survivors. 
 
 
FIGURE 21. Mean BNP in patients with a hospital stay of >10 days and < 
or = 10 days  among survivors. 
 
14. The ability of BNP to predict mortality was assessed by reviewing the BNP 
levels in the survivors and non-survivors. Among the 42 persons in the study 
group  8  patients died during the follow up period with most of them dying in 3 
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days  or less. Only one patient died after 17 days. Most of the patients who died 
had some form of multi-organ dysfunction.  
 
TABLE 14.A.Distribution of BNP values among survivors.   
 
DEATH YES NO 
NO.OF.PATIENTS 8 34 
MEAN 
BNP(pg/ml) 
569.5 148.82 
 TABLE 14.BMean BNP levels in survivors vs non-survivors 
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The mean BNP among the those who died  was  569.5pg/ml with one patient 
showing values as high as 986pg/ml. one patient also died inspite of  having a 
BNP value of 190pg/ml. The mean BNP in survivors was 148.28pg/ml with the 
highest value being 312 pg/ml. The P value of these two means was less than 
0.0001 which shows that the difference in BNP levels was extremely 
significant. This shows that very higher levels of BNP on admission are 
associated with  higher rates of mortality. 
 
FIGURE .22. Mean BNP levels in survivors vs non-survivors. 
15.The ability of BNP to predict the development of MODS was analysed by 
comparing the mean BNP in patients and survivors who who developed MODS 
with that of those who did not develop MODS. 
0 
100 
200 
300 
400 
500 
600 
YES 
NO 
8 
34 
569.5 
148.82 
M
E
A
N
 
B
N
P(
P
G
/
M
L)
 
MORTALITY 
NO.OF.PATIENTS 
MEAN BNP 
76 
 
There were 15 patients among the 42 who developed some sort of multiorgan 
dysfunction with the combination of renal and liver injury being the most 
commonest. Most of them were transient .  The mean BNP  in them was 
346.5pg/ml as against a mean of 163.6pg/ml  in the 27 who did not develop 
MODS . This  was quite significant but because of the confounding effect of the 
extreme values in those who died we compared the BNP levels in those who 
developed MODS and survived.     
 
DEVELOPMENT OF 
MODS 
YES NO 
NO.OF PATIENTS 9 25 
MEAN BNP(pg/ml) 190.9 133.7 
TABLE 15.Mean BNP levels in those who developed MODS vs those who      
did not 
 
The mean BNP in 25 survivors who recovered without developing MODS was 
133.7pg/ml against a mean BNP of 190.9 pg/ml in those who survived after 
developing MODS. The P value for the difference between the means was 0.01 
which shows that there was significant correlation between admission BNP 
levels and the development of MODS. 
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FIGURE 23.Mean BNP levels in those who developed MODS vs those who      
did not among the survivors. 
 
16. Having comprehensively studied the relationship between different 
parameters , the ability of BNP to predict adverse outcomes was compared with 
that of other clinical and laboratory prognostic indices. 
First we studied the ability of severity of leucocytosis to predict mortality . The 
mean leucocyte count in the 8 persons who died was 14,825.3 cells /mm
3
 which 
was modified to 15,583.3 cells /mm
3
 to avoid the confounding effect of the two 
extremely low values which were around 2500 cells/mm
3
. The mean WBC 
count in the 34 survivors was 12,800.8 cells/mm 
3
.  
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SURVIVED NO YES 
NUMBER 6 34 
MEAN WBC COUNT 
(cells/mm
3
) 
15,583.3 12,800.8 
 TABLE.16. Mean leucocyte count in survivors vs non-survivors 
(eliminating extremely low values) 
 
The difference between the means could have occurred by chance as suggested 
by a P value of 0.25. Hence the severity of leucocytosis did not correlate well 
with ultimate mortality.  
 
 
FIGURE 24. Mean leucocyte count in survivors vs non-survivors 
(eliminating extremely low values) 
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17. We analysed the ability of CRB-65 to predict mortality .The mean CRB-65 
score in the 34 survivors was 1.38 against a score of 2.62 in non- survivors. The 
P  value for the difference of means was 0.0005 which shows that a higher 
CRB-65 score of 2 or 3 on presentation was associated with a higher mortality. 
 
FIGURE.25.Distribution of CRB-65 values in the study group. 
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FIGURE.26. Comparision of mean CRB-65 score in survivors and non-
survivors 
 
18. Having realised that CRB- 65 score and BNP are comparable in predicting 
mortality we analysed if CRB-65 levels correlated with other morbidity 
parameters like the development of MODS and the duration of hospital stay. 
First the ability of CRB-65 score to predict the occurrence of  MODS was 
analysed. The mean CRB -65 score in those who developed MODS was 1.67 
against a mean of 1.28 in the 34 patients who recovered without developing 
MODS. The difference between the means had a P value of 0.24 which showed 
that the variation was not significant. 
 
FIGURE 27. Comparision between mean CRB-65 levels and the occurrence 
of MODS 
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The ability of CRB-65 score to predict the duration of hospital stay was studied. 
The mean CRB-65 score in those patients who had a hospital stay of more than 
10 days was found to be 2 against a score of 1 in those who hsd a hospital stay 
of less than or equal to 10 days. The P value of 0.0003 showed that the 
difference between the means was extremely significant. This shows that CRB-
65 score was comparable  to BNP in predicting the length of hospital stay . 
 
FIGURE 28. Comparision of CRB-65 scores with the length of hospital    
stay. 
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                      DISCUSSION  
 
Brain type natriuretic peptide (BNP) which has consistently been found elevated 
in patients with congestive cardiac failure and is used for assessing the 
prognosis of the same for quite a while now has been tested in a variety of 
conditions including pneumonia due to the new found knowledge about the 
various stimuli promoting its release. The results in the study were analysed 
keeping this in mind and some significant conclusions were derived regarding 
every aspect of BNP. 
 
The prime aim of the study was to assess the ability of BNP to predict poor 
outcomes including death in a patient with pneumonia. The study showed that 
the mean BNP value in non-survivors was (569.5 pg/ml) significantly higher 
than that (148.2 pg/ml) in survivors with a P value of 0.0001 . Values  of more 
than  200 pg/ml was  usually associated with clinically severe disease and 
values more than 400pg/ml are associated with a higher rate of mortality. This 
was very much in line with the results of the study published by Christ-Crain 
M et al in the journal of internal medicine in 2008 ; 
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One other parameter that correlated well with the mortality was the CRB- 65 
score on admission with scores 2 and 3 predicting a poorer outcome as 
compared to scores 0 or 1. The P value for the level of significance was 0.0005. 
This closely mirrored the results of the study published by Bauer et al in the 
journal of internal medicine in 2006. The net coclusion is that BNP values are 
as good or slightly better in predicting mortality than CRB-65 score. Further 
there was very good correlation between the BNP values and the CRB-65 in the 
study group  with a P value of 0.009.this shows that BNP levels vary directly in 
relation to the clinical severity of pneumonia as predicted by CRB- 65. 
BNP was also found in some studies to be significantly associated with a higher 
morbidity in pneumonia. Our study showed that BNP levels in those who had 
some sequlae in the form of  either ARDS , MODS or empyema was 
significantly higher than those who recovered without any complications. This 
confirmed the fact that a higher level of BNP predicts the likelihood of having a 
complicated course of pneumonia.  
The study in particular analysed the ability of BNP and CRB-65 score to predict 
the development of MODS. The mean BNP in survivors  who did not develop 
MODS was 133.7pg/ml against a mean BNP of 190.9 pg/ml in those who 
survived after developing MODS. The P value for the difference between the 
means was 0.01 which showed that there was significant correlation between 
admission BNP levels and the development of MODS. On the other hand the P 
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value in case of CRB-65 scores in the two groups was 0.24 suggesting that a 
higher CRB – 65 score did not significantly predict the occurrence of MODS. 
But CRB – 65 score was comparable to BNP in predicting the length of hospital 
stay , with patients having a BNP value of more than 200pg/ml  or a CRB-65 
score of more than 1 both having an increased risk of a prolonged healthcare 
stay  with a P value of 0.0001 and 0.0003 respectively. 
Though there was good correlation between the clinical indices , BNP ,mortality  
and morbidity , the same was not the case with leucocyte count. There was good 
correlation between the BNP levels and the severity of leucocytosis 
(>15,000/mm3) as confirmed by a P value of 0.002.  This affirms  the proposed 
theory that inflammation also has role in the release of BNP in pneumonia. 
But a higher leucocyte count failed to predict any significant rise in mortality as 
the P value was 0.24. 
BNP levels on presentation also correlated well with the rate of radiological and 
clinical resolution in patients recovering from an episode of pneumonia with a P 
value of 0.0075 and 0.003 respectively.   
There has been much speculations in recent studies that hypoxia may be one of 
the factors triggering the release of BNP. The mean BNP level in survivors with 
SpO2 was 174.7 pg/ml with a standard deviation of 48.6 against a mean value 
of 140.9 pg/ml with a standard deviation of 64.4 in those with SpO2 of less than 
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or equal to 90. The P value was 0.18 which showed that the difference was not 
that significant. So , it is possible that hypoxia may be an additive factor with 
respect to BNP production and can by itself cannot cause a significant elevation 
in BNP. 
The confounding effect of prior antibiotic therapy on BNP  levels in the study 
was  not significant as the difference in the mean BNP in the groups which 
received antibiotic therapy before coming to our hospital was not so different 
from that in the group which did not receive any antibiotic therapy. 
We also studied the variation in the BNP values caused by the two common 
group of organisms implicated in causing pneumonia. The mean BNP values in 
the patients who were infected with gram negative bacilli ( 173.9 pg/ml) was a 
bit higher than the BNP values in those infected with  gram positive cocci 
(127.6pg/ml). But the difference was not significance as shown by a P value of 
0.102. 
There was no gross difference in the elevation of BNP in alcoholics and non-
alcoholics . The same was the case with smokers and non-smokers. 
After having excluded patients with comorbidities known to influence BNP 
levels ,the mean BNP levels in patients with other comorbidities was analysed 
with hope of finding something interesting. But disappointingly there was no 
variation in the mean BNP levels with the other co-morbidities. 
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Margaret M Redfield et al in her study published in the J Am Coll Cardiol. 
2002 proposed that BNP levels increases with age and the mean value is higher 
in females
38
. But our study differed in both these aspects with our study 
showing higher mean BNP in those in the age group less than 50 and in males , 
probably bigger samples are needed to test the results. 
So it is clear that higher BNP levels correlated significantly with higher rates of 
mortality and morbidity in patients with community acquired pneumonia.BNP 
may be better than or as good as CRB-65  in this aspect . The extent of elevation 
of BNP is of more clinical significance than the cause of elevation because there 
may be multiple factors contributing to the elevation of BNP in pneumonia each 
of which has a prognostic significance of its own.                             
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                                            CONCLUSION 
The inferences that this study brought about were 
1.  Assessing the BNP levels on admission  is a rapid and reliable  means 
triaging pneumonia patients into various levels of care. 
2.  A high BNP level on admission is an independent risk factor for high 
mortality and morbidity in patients with pneumonia. 
3. BNP levels correlated with the clinical severity of the disease. 
4. BNP levels may be as effective or better than CRB-65 score in predicting 
the disease course.  
 
BNP may at present appear as a rather expensive alternative in our country but 
nevertheless it a more reliable method. Given the quantum of resources that 
may be wasted in cases of inappropriately triaged pneumonia , it is worth a go 
inspite of the cost. 
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ANNEXURE 1. 
                         ABBREVIATIONS USED IN THE TEXT 
ANP- Atrial Natriuretic Peptide 
ADM- Adreno Medullin 
ATS-American Thoracic Society. 
ARDS-Acute Respiratory Distress Syndrome. 
AVP- Arginine Vasopressin 
BAL-Broncho Alveolar Lavage 
BUN-Blood Urea Nitrogen 
BNP-Brain Natriuretic Peptide 
CAP- Community Acquired Pneumonia 
CFU-Colony Forming Units 
CRB-Confusion, Respiratory rate ,  Blood pressure 
CRP-C- Reactive Protein 
HAP-Hospital Acquired Pneumonia 
HCAP- Health Care Associated Pneumonia 
ICU- Intensive Care Unit. 
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IDSA-Infectious Disease Surveilance Agency 
MODS- Multi Organ Dysfunction Syndrome. 
PCT- Pro CalciTonin 
TNF-Tumour Necrosis Factor 
VAP- Ventilator Associated Pneumonia 
 
 
 
 
  
101 
 
ANNEXURE 2       
BNP IN PNEUMONIA AS A PROGNOSTIC MARKER AND ITS COMPARISION 
WITH CRB- 65 SCORE 
                                                           PROFORMA 
Name:      Age:   Sex: 
Address:       Occupation: 
Symptoms: 
 Dyspnea ; YES/NO       MRC grade- 
 Cough; YES/NO 
 Expectoration; YES/NO 
 Fever; YES / NO 
 Chest pain; YES/NO 
 Hemoptysis; YES/NO 
 Oliguria; YES/NO 
 Altered sensorium;YES/NO 
Past history: 
 Diabetes mellitus: YES/NO 
o Duration: 
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o Treatment:  OHA/Insulin 
o Compliance of treatment: 
o Associated complications(if any)  
 
 
 Hypertension; 
             Duration ; 
            Drugs used; 
 
 Coronary artery disease; YES/NO 
 Prior H/O CVA;YES/NO 
 Other co morbid illnesses; (specify) 
 
Treatment history: 
 H/O prior treatment to the present illness ; YES/NO 
 
Personal history: 
 Smoker YES/NO 
 Alcoholism; YES/NO 
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GENERAL EXAMINATION: 
PULSE: 
BLOOD PRESSURE: 
GENERAL EXAMINATION: 
 
 
SYSTEMIC EXAMINATION: 
CVS: RS: ABDOMEN:   CNS: 
 
 
INVESTIGATIONS: 
Hemogram RFT 
TC  cells/mm3 Glucose (F)  mg/dl 
DC  Glucose (PP)  mg/dl 
ESR  mm/hr Urea  mg/dl 
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Hb  g/dl Creatinine  mg/dl 
PCV  % Na+  mEq/l 
Platelets  lakhs/mm3 K+  mEq/l 
RBCs  million/mm3  
LIVER FUNCTION TESTS:  
 SPUTUM GRAM STAIN; 
SPUTUM C/S; 
BLOOD C/S; 
ULTRASONOGRAM OF ABDOMEN: 
ECG: 
X RAY CHEST; 
CT-CHEST; 
ECHO CARDIOGRAM: 
CRB-65 SCORE: 
SERUM BNP LEVELS ON ADMISSION: 
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 BNP IN PNEUMONIA AS A PROGNOSTIC MARKER AND ITS COMPARISION       
                                               WITH CRB- 65 SCORE 
                  PARAMETERS AT THE END OF 4 WEEKS AFTER ADMISSION 
Symptoms: 
 Dyspnea ; YES/NO       MRC grade- 
 Cough; YES/NO 
 Expectoration; YES/NO 
 Fever ; YES / NO 
 Chest pain; YES/NO 
 Hemoptysis; YES/NO 
  Malaise / fatigue higher than the pre illness level ; YES / NO 
 Able to carry out daily work as previously; YES / NO 
 Any other complaints; 
 Duration of inpatient stay: 
 
EXAMINATION; 
PULSE RATE: 
BLOOD PRESSURE: 
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RESPIRATORY RATE: 
HEAD TO FOOT EXAMINATION: 
RS EXAMINATION; 
            OTHER SYSTEM EXAMINATION; 
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ANNEXURE 3;MASTER CHARTS ( 1) 
PT'S NAME      AGE      SEX    DYSPNEA    HEMOPTYSIS  
     
     KRISHNAN 67 M YES NO 
SETHU 40 M YES  NO 
MOHANA SUDARAM 78 M YES  NO 
RAJAMMAL 62 F YES NO 
LOGANATHAN 52 M YES NO 
ELUMALAI 53 M NO NO 
GOWRI 60 F YES NO 
DHANALAKSHMI 45 F YES NO 
ELUMALAI  65 M YES NO 
SETTU 39 M YES NO 
BALAN 66 M NO NO 
MEENA 38 F YES NO 
THIRUPATHY 47 M YES NO 
ANNAMMAL 50 F YES NO 
SATHISH 30 M YES YES 
PUNNIYAKODI 60 M YES NO 
SURESH BABU 32 M YES NO 
SUSEELA 72 F YES NO 
RAJ 75 M YES YES 
MALA 38 F YES NO 
THOMAS 64 M YES NO 
CHINNAKULANDAI 68 F NO YES 
PARANTHAMAN 40 M YES  YES 
KRISHNAMOORTHY 58 M YES  NO 
VINOD KANNAN 25 M YES  YES 
JAYA  56 F YES NO 
RAJAMANICKAM 60 M YES NO 
VASUDEVAN 69 M NO YES 
ANJALAKSHMI 48 F YES  NO 
PARAMESWARAN 60 M YES NO 
SIVAGNANAM 56 F NO YES 
JAGAN 29 M YES YES 
KALAIYARASI 23 F YES NO 
RAYAN 49 M YES NO 
KAMATCHI 60 F YES NO 
SELLAMUTHU 35 M YES NO 
NARAYANAN  62 M YES NO 
VANNATHATCHI 60 F YES  NO 
RUKMANI 65 F YES NO 
PARAMESHWARI 50 F YES NO 
CHITRA 52 F NO YES 
AYYAPAN 67 M YES NO 
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CHART 2                                                                                  
 
PT'S NAME                     ASSOCIATED   COMORBIDITIES 
  
 
DIABETES HYPERTENSION CVA NEOPLASMS 
TOTAL 
COMORBIDITIES 
KRISHNAN NO YES NO  NO                1 
SETHU YES NO NO NO                       1 
MOHANA 
SUDARAM NO YES NO NO                        1 
RAJAMMAL NO NO NO NO 0 
LOGANATHAN YES YES NO NO 2 
ELUMALAI NO NO NO NO 0 
GOWRI YES NO NO NO 1 
DHANALAKSHMI NO NO NO NO 0 
ELUMALAI  YES YES NO NO 2 
SETTU NO NO NO NO 0 
BALAN YES YES NO NO 2 
MEENA NO NO NO NO 0 
THIRUPATHY NO NO NO NO 0 
ANNAMMAL NO NO NO NO 0 
SATHISH NO NO NO NO 0 
PUNNIYAKODI NO NO NO NO 0 
SURESH BABU NO NO NO NO 0 
SUSEELA YES NO NO NO 1 
RAJ NO NO NO NO 0 
MALA NO NO NO NO 0 
THOMAS NO NO NO NO 0 
CHINNAKULANDAI YES YES NO NO 2 
PARANTHAMAN YES NO NO NO 1 
KRISHNAMOORTHY NO NO NO YES 1 
VINOD KANNAN NO NO NO NO 0 
JAYA  YES YES NO NO 2 
RAJAMANICKAM YES NO NO NO 1 
VASUDEVAN NO NO NO NO 0 
ANJALAKSHMI NO NO NO YES 1 
PARAMESWARAN NO NO NO NO 0 
SIVAGNANAM YES YES NO NO 2 
JAGAN YES NO NO NO 1 
KALAIYARASI NO NO NO NO 0 
RAYAN YES NO NO NO 1 
KAMATCHI YES NO NO NO 1 
SELLAMUTHU NO NO NO NO 0 
NARAYANAN  NO YES NO NO 1 
VANNATHATCHI NO YES NO NO 1 
RUKMANI NO NO NO YES 1 
PARAMESHWARI NO NO NO NO 0 
CHITRA YES YES NO NO 2 
AYYAPAN NO YES YES NO 2 
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CHART 3 
 
 
PT'S NAME SMOKER ALCOHOLIC 
ANTIBIOTIC PRE-
TREATMENT CONFUSION 
     KRISHNAN YES YES NO NO 
SETHU NO YES NO NO 
MOHANA 
SUDARAM NO NO NO NO 
RAJAMMAL NO NO NO YES 
LOGANATHAN NO NO NO NO 
ELUMALAI YES YES NO NO 
GOWRI NO NO NO NO 
DHANALAKSHMI NO NO NO NO 
ELUMALAI  YES YES NO YES 
SETTU NO YES NO NO 
BALAN YES NO NO NO 
MEENA  NO NO NO NO 
THIRUPATHY YES YES NO NO 
ANNAMMAL NO YES NO NO 
SATHISH YES YES NO NO 
PUNNIYAKODI NO NO NO NO 
SURESH BABU NO YES NO NO 
SUSEELA NO NO NO NO 
RAJ YES NO YES NO 
MALA NO NO YES NO 
THOMAS YES NO YES YES 
CHINNAKULANDAI NO NO YES NO 
PARANTHAMAN YES YES YES NO 
KRISHNAMOORTHY NO NO YES NO 
VINOD KANNAN NO YES YES NO 
JAYA  NO NO YES NO 
RAJAMANICKAM NO YES YES YES 
VASUDEVAN NO NO YES NO 
ANJALAKSHMI NO NO YES YES 
PARAMESWARAN YES YES YES YES 
SIVAGNANAM NO NO YES NO 
JAGAN NO YES YES NO 
KALAIYARASI NO NO YES NO 
RAYAN YES NO YES NO 
KAMATCHI NO NO YES NO 
SELLAMUTHU NO NO YES NO 
NARAYANAN  YES NO YES NO 
VANNATHATCHI NO NO YES YES 
RUKMANI NO NO YES YES 
PARAMESHWARI NO NO YES NO 
CHITRA NO NO YES NO 
AYYAPAN NO YES YES YES 
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CHART 4 
PT'S NAME 
   RESPIRATORY RATE         
/MIN 
 SYSTOLIC BP (mm 
Hg)     SpO2 
WBC 
COUNT 
     KRISHNAN 34 120 92 14600 
SETHU 28 80 94 3900 
MOHANA 
SUDARAM 27 100 96 11200 
RAJAMMAL 42 80 92 12600 
LOGANATHAN 36 100 92 12100 
ELUMALAI 26 140 98 10400 
GOWRI 38 100 88 16400 
DHANALAKSHMI 29 110 96 7600 
ELUMALAI  36 100 95 20200 
SETTU 41 80 86 28200 
BALAN 26 120 97 7800 
MEENA 46 80 88 10600 
THIRUPATHY 32 86 94 9200 
ANNAMMAL 28 100 96 5400 
SATHISH 36 110 92 4300 
PUNNIYAKODI 39 100 92 12400 
SURESH BABU 36 80 94 22400 
SUSEELA 28 130 96 11100 
RAJ 26 110 94 16800 
MALA 32 100 94 8600 
THOMAS 38 70 86 18900 
CHINNAKULANDAI 30 80 96 14800 
PARANTHAMAN 38 80 92 21200 
KRISHNAMOORTHY 40 80 85 14600 
VINOD KANNAN 38 90 91 15600 
JAYA  34 140 88 10400 
RAJAMANICKAM 46 80 88 2800 
VASUDEVAN 24 110 96 9700 
ANJALAKSHMI 52 70 76 2100 
PARAMESWARAN 32 150 92 13800 
SIVAGNANAM 28 110 98 12400 
JAGAN 38 60 92 17400 
KALAIYARASI 42 80 84 9800 
RAYAN 44 80 84 22300 
KAMATCHI 34 140 94 11400 
SELLAMUTHU 48 70 76 18400 
NARAYANAN  44 80 82 19600 
VANNATHATCHI 40 170 90 11300 
RUKMANI 46 80 78 19900 
PARAMESHWARI 40 100 89 13600 
CHITRA 26 100 97 12500 
AYYAPAN 34 110 90 15800 
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CHART 5 
PT'S NAME       ESR CRB-65 ADMISSION BNP (pg/ml)  ISOLATED ORGANISM 
     KRISHNAN 48 2 152 NONE 
SETHU 38 1 92 GPC 
MOHANA SUDARAM 36 1 132 NONE 
RAJAMMAL 48 3 202 NONE 
LOGANATHAN 46 1 168 NONE 
ELUMALAI 22 0 68 GPC 
GOWRI 76 1 126 NONE 
DHANALAKSHMI 32 0 57 GPC 
ELUMALAI  62 3 138 GPC 
SETTU 78 2 264 GPC 
BALAN 26 1 88 GPC 
MEENA 50 2 132 GNB 
THIRUPATHY 32 2 94 NONE 
ANNAMMAL 24 0 60 GPC 
SATHISH 30 1 76 NONE 
PUNNIYAKODI 54 1 248 GNB 
SURESH BABU 56 2 254 GPC 
SUSEELA 34 1 104 GPC 
RAJ 38 1 118 GNB 
MALA 36 1 138 GPC 
THOMAS 44 3 482 NONE 
CHINNAKULANDAI 54 2 122 GNB 
PARANTHAMAN 68 2 312 GNB 
KRISHNAMOORTHY 60 2 684 GPC 
VINOD KANNAN 56 2 174 GPC 
JAYA  52 1 138 GPC 
RAJAMANICKAM 96 3 774 NONE 
VASUDEVAN 28 1 96 GPC 
ANJALAKSHMI 64 3 568 NONE 
PARAMESWARAN 46 2 154 GNB 
SIVAGNANAM 44 0 150 GNB 
JAGAN 42 2 232 GNB 
KALAIYARASI 52 2 224 NONE 
RAYAN 96 2 190 GPC 
KAMATCHI 36 1 116 GPC 
SELLAMUTHU 86 2 986 GNB,GPC 
NARAYANAN  78 2 278 NONE 
VANNATHATCHI 44 2 153 GNB 
RUKMANI 68 4 594 GPC 
PARAMESHWARI 30 1 174 NONE 
CHITRA 28 0 118 GNB 
AYYAPAN 58 3 186 NONE 
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PT'S NAME                                             PARAMETERS ON REVIEW AT 4 WEEKS 
 
CLINICAL RESOLUTION RADIOLOGICAL RESOLUTION 
HOSPITAL 
STAY(DAYS) 
KRISHNAN YES NO 10 
SETHU YES YES 3 
MOHANA SUDARAM YES NO 5 
RAJAMMAL YES NO 14 
LOGANATHAN YES YES 7 
ELUMALAI YES YES 3 
GOWRI NO NO 14 
DHANALAKSHMI YES YES 3 
ELUMALAI  NO NO 15 
SETTU YES YES 9 
BALAN YES YES 4 
MEENA YES NO 13 
THIRUPATHY YES YES 5 
ANNAMMAL YES YES 3 
SATHISH YES YES 4 
PUNNIYAKODI NO NO 16 
SURESH BABU NO NO 17 
SUSEELA YES YES 5 
RAJ YES YES 4 
MALA YES NO 6 
THOMAS NA NA 3 
CHINNAKULANDAI YES NO 9 
PARANTHAMAN NO NO 11 
KRISHNAMOORTHY NA NA 4 
VINOD KANNAN YES NO 20 
JAYA  YES NO 8 
RAJAMANICKAM NA NA 3 
VASUDEVAN YES NO 7 
ANJALAKSHMI NA NA 1 
PARAMESWARAN NO NO 14 
SIVAGNANAM YES NO 8 
JAGAN YES NO 12 
KALAIYARASI NO NO 12 
RAYAN NA NA +2 
KAMATCHI YES YES 6 
SELLAMUTHU NA NA 17 
NARAYANAN  NA NA 2 
VANNATHATCHI YES NO 8 
RUKMANI NA NA 2 
PARAMESHWARI YES YES 12 
CHITRA YES NO 8 
AYYAPAN YES NO 12 
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CHART 7 
PT'S NAME 
                           
COMPLICATIONS 
  
 
 
EFFUSION EMPYEMA 
    
ARDS    MODS DEATH 
KRISHNAN NO NO NO NO NO 
SETHU NO NO NO NO NO 
MOHANA SUDARAM NO NO NO NO NO 
RAJAMMAL NO NO YES YES NO 
LOGANATHAN NO NO YES YES NO 
ELUMALAI NO NO NO NO NO 
GOWRI NO NO YES YES NO 
DHANALAKSHMI NO NO NO NO NO 
ELUMALAI  YES YES NO YES NO 
SETTU NO NO YES NO NO 
BALAN NO NO NO NO NO 
MEENA NO NO YES NO NO 
THIRUPATHY NO NO NO  NO NO 
ANNAMMAL NO NO NO NO NO 
SATHISH NO NO NO NO NO 
PUNNIYAKODI YES YES NO YES NO 
SURESH BABU YES YES NO NO NO 
SUSEELA NO NO NO NO NO 
RAJ NO NO NO NO NO 
MALA YES NO NO NO NO 
THOMAS YES NO YES NO YES 
CHINNAKULANDAI NO NO NO NO NO 
PARANTHAMAN YES NO NO YES NO 
KRISHNAMOORTHY YES NO NO YES YES 
VINOD KANNAN NO NO YES YES NO 
JAYA  YES NO NO NO NO 
RAJAMANICKAM NO NO YES YES YES 
VASUDEVAN NO NO NO NO NO 
ANJALAKSHMI NO NO YES YES YES 
PARAMESWARAN YES YES NO NO NO 
SIVAGNANAM YES NO NO NO NO 
JAGAN YES YES NO YES NO 
KALAIYARASI NO NO YES NO NO 
RAYAN NO NO YES YES YES 
KAMATCHI NO NO NO NO NO 
SELLAMUTHU YES  YES NO  YES YES 
NARAYANAN  NO NO YES YES YES 
VANNATHATCHI NO NO  NO NO NO 
RUKMANI YES NO YES NO YES 
PARAMESHWARI YES NO YES NO NO 
CHITRA NO NO NO YES NO 
AYYAPAN NO NO NO NO NO 
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ANNEXURE 4; ETHICAL COMMITTEE APPROVAL FORM 
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ANNEXURE 5; PHOTO COPY EVIDENCE OF ANTI-PLAGIARISM 
WEBSITE 
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ANNEXURE 6;DIGITAL RECEIPT OF ANTI-PLAGIARISM WEBSITE 
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